Hartaj Singh
Stock Analyst at Oppenheimer
(2.18)
# 1,425
Out of 4,479 analysts
73
Total ratings
40.96%
Success rate
-5.48%
Average return
Main Sectors:
Top Industries:
20 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SPRB Spruce Biosciences | Maintains: Outperform | $4 → $3 | $0.53 | +468.94% | 5 | Jun 13, 2024 | |
| CLLS Cellectis | Maintains: Outperform | $11 → $10 | $1.89 | +429.10% | 4 | Jun 12, 2024 | |
| MRNA Moderna | Maintains: Outperform | $163 → $179 | $117.07 | +52.90% | 6 | Jun 12, 2024 | |
| BMEA Biomea Fusion | Maintains: Outperform | $70 → $60 | $4.43 | +1,254.40% | 5 | May 30, 2024 | |
| VIRX Viracta Therapeutics | Maintains: Outperform | $13 → $11 | $0.49 | +2,144.90% | 3 | May 23, 2024 | |
| ATXS Astria Therapeutics | Maintains: Outperform | $29 → $25 | $8.97 | +178.71% | 3 | May 21, 2024 | |
| SRPT Sarepta Therapeutics | Upgrades: Outperform | $180 | $154.20 | +16.73% | 5 | May 14, 2024 | |
| UTHR United Therapeutics | Maintains: Outperform | $375 → $400 | $317.05 | +26.16% | 3 | May 2, 2024 | |
| GANX Gain Therapeutics | Maintains: Outperform | $9 | $1.20 | +653.14% | 4 | Apr 23, 2024 | |
| GILD Gilead Sciences | Maintains: Outperform | $105 | $68.40 | +53.51% | 4 | Apr 19, 2024 | |
| VRTX Vertex Pharmaceuticals | Maintains: Outperform | $500 | $473.78 | +5.53% | 8 | Apr 15, 2024 | |
| INO Inovio Pharmaceuticals | Maintains: Outperform | $40 | $8.43 | +374.50% | 4 | Mar 8, 2024 | |
| TRDA Entrada Therapeutics | Initiates: Outperform | $22 | $14.00 | +57.14% | 1 | Jan 5, 2024 | |
| OPT Opthea | Maintains: Outperform | $31 → $16 | $1.93 | +731.17% | 3 | Sep 13, 2023 | |
| REGN Regeneron Pharmaceuticals | Maintains: Outperform | $950 → $1,050 | $1,044.66 | +0.51% | 5 | Aug 21, 2023 | |
| ELOX Eloxx Pharmaceuticals | Maintains: Outperform | $50 → $55 | $0.73 | +7,434.25% | 3 | Jul 11, 2023 | |
| ONCT Oncternal Therapeutics | Downgrades: Perform | n/a | $7.05 | - | 3 | Apr 4, 2023 | |
| NBSE NeuBase Therapeutics | Downgrades: Perform | n/a | $0.38 | - | 2 | Oct 21, 2022 | |
| SLS SELLAS Life Sciences Group | Initiates: Outperform | n/a | $1.12 | - | 1 | Nov 1, 2018 | |
| SMMT Summit Therapeutics | Maintains: Outperform | n/a | $7.54 | - | 1 | Jan 26, 2018 |
Spruce Biosciences
Jun 13, 2024
Maintains: Outperform
Price Target: $4 → $3
Current: $0.53
Upside: +468.94%
Cellectis
Jun 12, 2024
Maintains: Outperform
Price Target: $11 → $10
Current: $1.89
Upside: +429.10%
Moderna
Jun 12, 2024
Maintains: Outperform
Price Target: $163 → $179
Current: $117.07
Upside: +52.90%
Biomea Fusion
May 30, 2024
Maintains: Outperform
Price Target: $70 → $60
Current: $4.43
Upside: +1,254.40%
Viracta Therapeutics
May 23, 2024
Maintains: Outperform
Price Target: $13 → $11
Current: $0.49
Upside: +2,144.90%
Astria Therapeutics
May 21, 2024
Maintains: Outperform
Price Target: $29 → $25
Current: $8.97
Upside: +178.71%
Sarepta Therapeutics
May 14, 2024
Upgrades: Outperform
Price Target: $180
Current: $154.20
Upside: +16.73%
United Therapeutics
May 2, 2024
Maintains: Outperform
Price Target: $375 → $400
Current: $317.05
Upside: +26.16%
Gain Therapeutics
Apr 23, 2024
Maintains: Outperform
Price Target: $9
Current: $1.20
Upside: +653.14%
Gilead Sciences
Apr 19, 2024
Maintains: Outperform
Price Target: $105
Current: $68.40
Upside: +53.51%
Vertex Pharmaceuticals
Apr 15, 2024
Maintains: Outperform
Price Target: $500
Current: $473.78
Upside: +5.53%
Inovio Pharmaceuticals
Mar 8, 2024
Maintains: Outperform
Price Target: $40
Current: $8.43
Upside: +374.50%
Entrada Therapeutics
Jan 5, 2024
Initiates: Outperform
Price Target: $22
Current: $14.00
Upside: +57.14%
Opthea
Sep 13, 2023
Maintains: Outperform
Price Target: $31 → $16
Current: $1.93
Upside: +731.17%
Regeneron Pharmaceuticals
Aug 21, 2023
Maintains: Outperform
Price Target: $950 → $1,050
Current: $1,044.66
Upside: +0.51%
Eloxx Pharmaceuticals
Jul 11, 2023
Maintains: Outperform
Price Target: $50 → $55
Current: $0.73
Upside: +7,434.25%
Oncternal Therapeutics
Apr 4, 2023
Downgrades: Perform
Price Target: n/a
Current: $7.05
Upside: -
NeuBase Therapeutics
Oct 21, 2022
Downgrades: Perform
Price Target: n/a
Current: $0.38
Upside: -
SELLAS Life Sciences Group
Nov 1, 2018
Initiates: Outperform
Price Target: n/a
Current: $1.12
Upside: -
Summit Therapeutics
Jan 26, 2018
Maintains: Outperform
Price Target: n/a
Current: $7.54
Upside: -